Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma
Mené sur 861 patients atteints d'un carcinome à cellules rénales de stade avancé, cet essai de phase III compare l'efficacité, du point de vue de la survie globale et de la survie sans progression, du sunitinib en monothérapie et d'un traitement combinant pembrolizumab et axitinib (durée médiane de suivi : 30,6 mois)
The treatment landscape of advanced renal cell carcinoma has undergone a revolution.For more than 10 years, single-agent therapy with anti-angiogenic tyrosine kinaseinhibitors (TKIs), including sunitinib or pazopanib, was the unchallenged gold-standardfirst-line approach. However, this paradigm has changed since the advent of immunotherapies,with immune checkpoint inhibitors (ICIs), alone or combined with each other or withTKIs, showing superior efficacy compared with TKI monotherapies.
The Lancet Oncology , commentaire, 2019